Right Fit.
Reliable Results.

PROPEL Contour has an evolutionary design that conforms to the frontal and maxillary sinus ostium for maximum apposition and drug delivery.

PROPEL Contour Mometasone Furoate Adaptable Sinus Implant LogoPROPEL Contour is the latest addition to the PROPEL family of products offering localized, controlled drug delivery directly to the sinus ostium. The adaptable, hourglass implant is designed to conform to the sinus ostium, maximizing apposition and drug delivery following frontal and maxillary sinus surgery.

The implant gradually delivers an advanced corticosteroid (mometasone furoate) with anti-inflammatory properties directly to the sinus lining over 30 days as it dissolves.

PROPEL Contour has been clinically proven to reduce the potential for sinus occlusion or restenosis and is also proven to reduce the need for postoperative interventions, delivering superior clinical outcomes following frontal sinus surgery.1,2

PROPEL Contour Adaptable Sinus Stent Product Image

PROGRESS Study:
PROPEL Contour Demonstrates Superior Outcomes in the Frontal Sinus Ostia1

Similar to other PROPEL implants, PROPEL Contour was studied in a prospective, randomized, blinded, controlled trial to evaluate its benefits following frontal sinus surgery. The 80-patient PROGRESS—PROPEL Contour study demonstrated reductions in the rate of occlusion as well as need for postoperative interventions compared to frontal sinus surgery alone.1,2

PROPEL Contour 30-Day Results Graph

PROPEL Contour Sinus Implant Product Details

  • Indicated for the Frontal and Maxillary Sinus Ostia
  • Low Profile (2.8mm) Delivery System with Malleable Tip
  • 8mm Nominal Length
U.S. Instructions for Use
PROPEL Contour Adaptable Sinusitis Implant Product Photo

Learn More About
PROPEL Sinus Implants

We have compiled resources to help physicians and patients better understand how the PROPEL steroid-releasing implant works to improve sinus surgery outcomes.

Physician Resources
Patient Resources

*Reliable Results refers to PROPEL family, based on Pilot, Advance II, and PROGRESS studies.
1 Data on file. N=80 in ITT population, with N=61 evaluable patients where both sinuses available for composite endpoint.
2 Primary results judged by independent reviewer.
3 Secondary endpoints judged by clinical investigators. P-values for secondary efficacy endpoints were adjusted for multiplicity. Green arrow indicates relative reduction 30 days following treatment.

The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.

The PROPEL® Contour implant, delivery system, and/or the use of the PROPEL® Contour implant/delivery system in a method may be covered by one or more U.S. and/or foreign patents, including U.S. Patent Nos. 7,544,192, 7,662,141, 7,662,142, 7,713,255, 7,951,133, 7,951,135, 8,109,918, 8,535,707, 8,585,731, 8,763,222, and 8,986,341. Other patent applications are pending. This page is intended to serve as notice under 35 U.S.C. § 287(a).